Scarica l'app Stockscreener
17.00
1.39%
-0.24
Dopo l'orario di chiusura:
17.34
0.34
+2.00%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$17.24
Aprire:
$18
Volume 24 ore:
1.49M
Relative Volume:
0.54
Capitalizzazione di mercato:
$1.88B
Reddito:
$70.92M
Utile/perdita netta:
$-342.21M
Rapporto P/E:
-4.516
EPS:
-3.7644
Flusso di cassa netto:
$-304.30M
1 W Prestazione:
+6.45%
1M Prestazione:
+23.82%
6M Prestazione:
-46.41%
1 anno Prestazione:
+25.28%
Intervallo 1D:
$16.87
$18.00
Intervallo di 1 settimana:
$15.98
$18.20
Portata 52W:
$13.18
$34.29
Viridian Therapeutics Inc Stock (VRDN) Company Profile
Nome
Viridian Therapeutics Inc
Settore
Industria
Telefono
617.272.4600
Indirizzo
221 CRESCENT STREET, WALTHAM
Compare VRDN vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VRDN
Viridian Therapeutics Inc
|
17.00 | 1.90B | 70.92M | -342.21M | -304.30M | -3.7644 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-10 | Reiterato | Wedbush | Outperform |
| 2025-12-03 | Iniziato | William Blair | Outperform |
| 2025-11-24 | Iniziato | Truist | Buy |
| 2025-08-25 | Ripresa | Jefferies | Buy |
| 2024-12-19 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-11-25 | Iniziato | TD Cowen | Buy |
| 2024-09-11 | Reiterato | Needham | Buy |
| 2024-06-11 | Iniziato | Wolfe Research | Outperform |
| 2024-06-06 | Iniziato | Goldman | Buy |
| 2024-05-09 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2024-05-09 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2023-06-14 | Iniziato | BTIG Research | Buy |
| 2023-06-14 | Ripresa | Credit Suisse | Outperform |
| 2023-05-30 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-04-17 | Iniziato | Wells Fargo | Overweight |
| 2023-03-30 | Iniziato | Stifel | Buy |
| 2022-12-19 | Iniziato | Cowen | Outperform |
| 2022-12-19 | Iniziato | Needham | Buy |
| 2022-12-16 | Iniziato | Credit Suisse | Outperform |
| 2022-12-01 | Iniziato | H.C. Wainwright | Buy |
| 2022-06-23 | Iniziato | B. Riley Securities | Buy |
| 2021-11-18 | Iniziato | SVB Leerink | Outperform |
| 2021-10-12 | Iniziato | Evercore ISI | Outperform |
| 2021-01-25 | Iniziato | Ladenburg Thalmann | Buy |
Mostra tutto
Viridian Therapeutics Inc Borsa (VRDN) Ultime notizie
Does Viridian’s Upsized Note and Equity Offering Change The Bull Case For Viridian Therapeutics (VRDN)? - Sahm
Viridian Therapeutics prices upsized $350M concurrent stock and convertible notes offerings - MSN
Viridian Therapeutics (VRDN) Prices Upsized Concurrent Public Offerings Totaling $350M - Insider Monkey
Viridian Therapeutics releases topline phase 3 TED data elegrobart - Eyes On Eyecare
VRDN Stock Price, Quote & Chart | VIRIDIAN THERAPEUTICS INC (NASDAQ:VRDN) - ChartMill
This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million - AOL.com
Viridian Therapeutics launches $250M concurrent debt and equity offerings - MSN
PDUFA decision nears as Viridian Therapeutics (VRDN) advances TED pipeline and reports Q1 results - MSN
HighVista Strategies Sells 238,243 Shares of Viridian Therapeutics in Q1 2026News and Statistics - IndexBox
This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million - The Motley Fool
Why is Viridian Therapeutics stock sinking Monday? - MSN
VRDN: Wedbush Maintains Rating but Lowers Price Target | VRDN St - GuruFocus
Evercore Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $26 - Moomoo
Liquidity Mapping Around (VRDN) Price Events - Stock Traders Daily
VRDN Maintained by Evercore ISI Group -- Price Target Lowered to $26 - GuruFocus
Viridian Therapeutics Analyst Ratings and Price Targets | NASDAQ:VRDN - Benzinga
Viridian Therapeutics Inc (VRDN) Stock Price, Quote, News & History - Benzinga
Bellevue Group (VRDN) files Schedule 13G for 6.6% ownership - Stock Titan
Viridian Therapeutics stock (US92769V1044): Q1 earnings beat and Phase 3 data boost - AD HOC NEWS
Fairmount Healthcare Fund II invests $20m in Viridian Therapeutics By Investing.com - Investing.com Australia
Viridian Therapeutics(VRDN.US) 10% Shareholder Buys US$20 Million in Common Stock - Moomoo
Fairmount-linked fund boosts Viridian (VRDN) stake with 1.18M-share open-market buy - Stock Titan
Fairmount boosts Viridian Therapeutics (VRDN) stake to 14.04% after $20M share purchase - Stock Titan
Stifel Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Cuts Target Price to $39 - Moomoo
How Strong REVEAL-2 Data and Fresh Capital Raises Could Shape Viridian Therapeutics (VRDN) Investors - Sahm
VRDN6389238 Bond Coupon Analysis — Rate & Payments - TradingView
VRDN6389238 Bond Analysis — Key Metrics - TradingView
Viridian Therapeutics stock (US92769V1044): Q1 beat with 95.8% revenue surge - AD HOC NEWS
Viridian Therapeutics, Inc. Bonds — Corporate Bond Rates - TradingView
Viridian Therapeutics Raises $359 Million in Offerings - TipRanks
[8-K] Viridian Therapeutics, Inc.\DE Reports Material Event - Stock Titan
VRDN6389238 Bond Price and Chart — FINRA:VRDN6389238 - TradingView
Number of shareholders of Viridian Therapeutics, Inc. – NASDAQ:VRDN - TradingView
Viridian Therapeutics, Inc. (VRDN) Discusses Positive Top Line Results From REVEAL-2 Phase III Trial in Chronic Thyroid Eye DiseaseSlideshow (NASDAQ:VRDN) 2026-05-09 - Seeking Alpha
Reassessing Viridian Therapeutics (VRDN) After Volatile Share Price Swings - Sahm
Deep Track files 5.30% stake in Viridian Therapeutics (NYSE: VRDN) as Schedule 13G - Stock Titan
Viridian Therapeutics (NASDAQ: VRDN) offers $225M convertibles; concurrent equity deal - Stock Titan
Viridian Therapeutics (VRDN) files 7.35M-share sale, concurrent $225M notes - Stock Titan
Why Viridian Therapeutics (VRDN) Is Up 25.9% After Phase 3 Elegrobart Win And Fresh Fundraising - Yahoo Finance
Viridian Therapeutics | FWP: Filing under Securities Act Rules 163/433 of free writing prospectuses - Moomoo
Viridian prices $225M convertible notes, $125M equity offering - Investing.com UK
MSN Money - MSN
Viridian Therapeutics (VRDN) Announces $350M Public Offerings fo - GuruFocus
Viridian Therapeutics Plans to Use Proceeds to Repay Debt, Fund Studies for Thyroid Eye Disease Franchise, Advance R&D >VRDN - Moomoo
Earnings Update: Viridian Therapeutics, Inc. (NASDAQ:VRDN) Just Reported And Analysts Are Boosting Their Estimates - Yahoo Finance
Viridian Therapeutics Prices Upsized Public Offering of 7.35M Shares at $17 Each >VRDN - Moomoo
Viridian Therapeutics | 305B2: Application for designation of a new trustee under the Trust Indenture Act - Moomoo
Viridian Therapeutics Inc Azioni (VRDN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.98%
0.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):